黛力新联合促动力和制酸药物治疗功能性消化不良的近期疗效评价

Evaluation of short-term clinical effect of deanxit combined with prokinetic drugs and acid-inhibition medicine in functional dyspepsia

目的研究采用黛力新联合促动力和制酸药物治疗功能性消化不良的近期疗效。方法择取80例功能性消化不良患者采用随机数字法分为两组,各40例。对照组采用雷贝拉唑和莫沙必利治疗,观察组则在此基础上加用黛力新治疗。比较两组近期疗效情况。结果观察组治疗总有效率明显高于对照组(P<0.05);治疗后,两组SAS、SDS评分均降低,且观察组SAS、SDS评分明显低于对照组(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论功能性消化不良采用黛力新联合促动力和制酸药物治疗能够提升其近期疗效,不良反应发生率低,值得推广。

Objective To study the short-term clinical effect of deanxit combined with prokinetic drugs and acid-inhibition medicine in functional dyspepsia. Methods Eighty cases of patients with functional dyspepsia were selected and divided into two groups by random number method, with 40 cases in each group. The control group was treated with rabeprazole and mosapride, while the observation group was treated with deanxit on this basis. The short-term clinical effects of the two groups were compared. Results The total effective rate in the observation group was significantly higher than that in the control group（P〈0.05）. After treatment, the SAS and SDS scores in both groups decreased, those in the observation group were significantly lower than the control group（P〈0.05）. There was no significant difference in the total incidence of adverse reactions between the two groups（P〉0.05）. Conclusion Deanxit combined with prokinetic drugs and acid-inhibition medicine in functional dyspepsia can promote the improvement of short-term clinical effect, and at the same time, the incidence of adverse reactions is low, thus it is worth promoting.